Thakar Lab publishes article on the Impact of vaccine type on HIV-1 vaccine elicited antibody durability and B cell gene signature
Monday, August 10, 2020
Efficacious HIV-1 vaccination requires elicitation of long-lived antibody responses. However, our understanding of how different vaccine types elicit durable antibody responses is lacking. To assess the impact of vaccine type on antibody responses, we measured IgG isotypes against four consensus HIV antigens from 2 weeks to 10 years post HIV-1 vaccination and used mixed effects models to estimate half-life of responses in four human clinical trials. Compared to protein-boosted regimens, half-lives of gp120-specific antibodies were longer but peak magnitudes were lower in Modified Vaccinia Ankara (MVA)-boosted regimens. Furthermore, gp120-specific B cell transcriptomics from MVA-boosted and protein-boosted vaccines revealed a distinct signature at a peak (2 weeks after last vaccination) including CD19, CD40, and FCRL2-5 activation along with increased B cell receptor signaling. Additional analysis revealed contributions of RIG-I-like receptor pathway and genes such as SMAD5 and IL-32 to antibody durability. Thus, this study provides novel insights into vaccine induced antibody durability and B-cell receptor signaling.Read More: Thakar Lab publishes article on the Impact of vaccine type on HIV-1 vaccine elicited antibody durability and B cell gene signature
Sangster Weighs in on COVID-19 Vaccine, Antibodies
Wednesday, August 5, 2020
With millions of lives on the line, researchers have been working at an unprecedented pace to develop a COVID-19 vaccine.
But that speed—and some widely touted breakthroughs—belie the enormous complexity and potential risks involved. Researchers have an incomplete understanding of the coronavirus and are using technology that’s largely unproven.
Among many worries: A handful of studies on COVID-19 survivors suggest that antibodies—key immune system proteins that fight infection—begin to disappear within months. That’s led scientists to worry that the protection provided by vaccines could fade quickly as well. Some even question whether vaccines will really end the pandemic. If vaccines produce limited protection against infection, experts note, people will need to continue wearing masks and social distancing even after vaccines roll out.
People with severe symptoms from COVID-19 tend to have higher antibody levels than those with milder cases.
Some people fail to generate antibodies because they have compromised immune systems, said Mark Sangster, a research professor at the University of Rochester Medical Center.
Even when people do generate antibodies against the novel coronavirus, studies suggest the antibodies may not last long.Read More: Sangster Weighs in on COVID-19 Vaccine, Antibodies
IMV Grad Student Megan Ulbrich Wins the Melville A. Hare Award for Excellence in Teaching
Friday, June 5, 2020
Please join the department in congratulating Megan Ulbrich, this year’s winner of the Melville A. Hare Award for Excellence in Teaching. This award is given annually by the Department of Microbiology and Immunology to a graduate student who has displayed outstanding qualities of mentoring and teaching in one or more MBI courses. The award will be officially conferred at URMC Convocation in the late summer.
Megan is currently an IMV graduate student in Michelle Dziejman's lab working on multidisciplinary approaches to uncover novel effector protein functions. Megan grew up in Buffalo, NY and received her B.S. in Microbiology from the University of Pittsburgh.
Dr. Deborah Fowell appointed next Chair of the Department of Microbiology and Immunology
Tuesday, May 12, 2020
We congratulate Dr. Deborah Fowell on her new position as Chair of the Department of Microbiology and Immunology at Cornell University College of Veterinary Medicine, where she will start this fall. As a valued faculty member and Dean’s Professor in the Department of Microbiology and Immunology, Center for Vaccine Biology and Immunology, this is a bittersweet goodbye – but a wonderful new opportunity for Deb!
Since joining UR in April 2000, Dr. Fowell has achieved great success in her research program. One example is her organization and leadership of an accomplished, interdisciplinary team of investigators in an NIH funded program project to visualize the immune system in action, which was recently renewed. Her efforts have led to tremendous advancements in the field and will continue to enhance our understanding of tissue inflammation and immune responses, while also providing new therapeutic targets for mitigation of a wide variety of inflammatory diseases.
Not only is Dr. Fowell an outstanding researcher, she is also deeply committed to excellence in graduate education. She recently took over as Program Director and successfully renewed the University’s Predoctoral Training Grant in Immunology. In addition, she has received multiple mentoring awards at the UR, including the 2015 Graduate Alumni Award, which is the most prestigious student teaching and mentoring award here at the School of Medicine and Dentistry.
Dr. Fowell has a strong reputation among her peers as a highly innovative researcher with rigorous intellectual standards, and as a consistent advocate of the highest quality science and long-term success for academic research. Her collaborative approach to research, commitment to enriching learning and intellectual discourse, coupled with her drive and energy, will ensure her success at Cornell.
It’s with pride, warm wishes and anticipation of exciting future collaborations that we wish Deb every success in her new role!Read More: Dr. Deborah Fowell appointed next Chair of the Department of Microbiology and Immunology